Ulcerative Colitis (UC)NCT07608198
Validation of the Reliability and Validity of the New Endoscopic Scoring System for Ulcerative Colitis (CAT-DESIRE Score) and Verification of Its Clinical Practicability
An observational study of Ulcerative Colitis (UC), run by Xijing Hospital of Digestive Diseases at 9 sites in China.
Trial summary
Ulcerative Colitis (UC) is a chronic, non-specific intestinal inflammatory disease of unknown cause, featuring abdominal pain, diarrhea, and bloody stools. Endoscopy shows diffuse, continuous lesions with erosion and shallow ulcers, worst in the rectum and diminishing proximally. Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Ulcerative Colitis (UC)
- How many people
- 235 participants
- Where
- 9 sitesChina
- Study dates
- 1 Feb 2024to 1 May 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: A total of 235 UC patients were recruited from 9 specialized IBD diagnosis and therapy centers across China, with all patients undergoing paired endoscopic evaluations. Nine specialized IBD diagnosis and therapy centers are the Air Force Military Medical University First Affiliated Hospital, the Beijing Peking Union Medical College Hospital, the Xi'an Jiaotong University Affiliated Second Hospital, the Shanghai Ruijin Hospital, the Xinjiang Urumqi Affiliated First Hospital, the Sichuan Huaxi Hospital, the Wuhan Xiehe Hospital, the Shanghai Jiao Tong Renji Hospital, and the Seventh Medical Center of PLA General Hospital.
Who may be able to join
- 1. Adult patients (aged 18 - 75 years);
- 2. Diagnosed with ulcerative colitis for at least 3 months;
- 3. Have had endoscopic examination results for at least 2 times, with clear endoscopic images (including endoscopic pictures of the terminal ileum, cecum, ascending colon, transverse colon, descending colon, sigmoid colon, and rectum at least one picture for each of these 7 areas);
- 4. Complete clinical data.
Who cannot join
- 1. Crohn's disease, intestinal Behcet's disease, intestinal tuberculosis, toxic megacolon and unclassified inflammatory bowel disease.
- 2. The length of the colon lesion could not be evaluated.
Trial locations and contacts
9 sites in 1 country.
9 sites in 1 country
China9 sites
The Seventh Medical Center of PLA General Hospital
Beijing, Beijing Municipality, 100700
Peking Union Medical College Hospital
Beijing, Beijing Municipality, 100730
West China Hospital
Chengdu, Sichuan, 610041
Ruijin Hospital
Shanghai, Shanghai Municipality, 200025
Renji Hospital
Shanghai, Shanghai Municipality, 200127
The First Affiliated Hospital of Xinjiang Medical University
Ürümqi, Xinjiang, 830000
Wuhan Union Hospital of China
Wuhan, Hubei, 430022
The Second Affiliated Hospital of Xi'an Jiaotong University
Xi'an, Shaanxi, 710004
Xijing Hospital of Digestive Disease
Xi'an, Shaanxi, 710032
About this study
Ulcerative Colitis (UC) is a chronic, non-specific intestinal inflammatory disease of unknown cause, featuring abdominal pain, diarrhea, and bloody stools. Endoscopy shows diffuse, continuous lesions with erosion and shallow ulcers, worst in the rectum and diminishing proximally. Current treatments (aminosalicylates, corticosteroids, immunosuppressants, biologics, small molecule drugs) are not curative. Endoscopic mucosal healing is a key treatment goal, improving steroid-free remission, reducing colectomy rates, recurrence, hospitalization, and colorectal cancer risk.
Common endoscopic scoring systems: Baron score (poor consistency), Mayo Endoscopic Score (MES, simple but lacks prognostic info), and Ulcerative Colitis Endoscopic Severity Index (UCEIS, more detailed and consistent but cumbersome). Disease extent is important for severity, as proximal extension increases relapse, treatment escalation, and cancer risk. However, MES and UCEIS assess only the worst segment, underestimating total disease burden.
Read more
Other scores (UCCIS, MMES, DUBLIN) attempt to incorporate lesion extent but have limitations (small samples, lack of validation, unclear severity cutoffs). Data on short-/medium-term endoscopic changes and long-term outcomes are scarce.
We therefore propose a new endoscopic scoring system, the CAT-DESIRE score, aiming to evaluate its reliability, validity, and predictive role in medium-/long-term prognosis and treatment response, providing a simple, accurate tool for assessing disease burden and guiding clinical decisions.
Read the detailed description
Ulcerative Colitis (UC) is a chronic, non-specific inflammatory disease of the intestine with unknown causes and mechanisms. Its main clinical manifestations include abdominal pain, diarrhea, and bloody stools. The typical endoscopic appearance of UC is diffuse and continuous lesions, accompanied by erosion and shallow ulcers. The lesions are most severe in the rectum and gradually become less severe towards the proximal part. Currently, the main therapeutic drugs for UC include aminosalicylic acid preparations, corticosteroids, immunosuppressants, biologics, and small molecule drugs, but there is no cure. The choice of treatment plan is based on a comprehensive assessment of the disease. Endoscopic examination can objectively determine the lesion range and assess the disease activity, which is of great significance for monitoring treatment response and providing individualized optimal treatment plans. Endoscopic mucosal healing has become an important goal in the treatment of UC, and it has been proven to achieve better long-term efficacy, including increasing the rate of steroid-free remission, reducing the need for colectomy, and lowering the risks of recurrence, hospitalization, and colorectal cancer.
There are several endoscopic scoring systems currently applied in clinical and research assessment of UC. Different endoscopic scoring tools have different advantages and limitations. The initial endoscopic classification of UC was the Baron score, which, due to not measuring the consistency indicators among researchers, had a 40% disagreement in classifying normal, mild, moderate, or severe activity, and there was little supporting data. The Mayo endoscopic score (MES) and the Ulcerative Colitis Endoscopic Severity Index (UCEIS) are currently the two main endoscopic scoring systems for evaluating mucosal inflammation symptoms and disease activity. MES is easy to use but lacks information on disease prognosis. UCEIS distinguishes mucosal inflammation and disease activity more detailedly through a greater number of layers (0-8) than MES (0-3), and shows higher internal and inter-rater consistency, but is more computationally cumbersome.
The disease range is potentially important in evaluating the severity of UC. The IBSEN study showed that disease expansion is an important independent factor for colectomy in UC patients. Qiu and his colleagues further proved that proximal disease expansion would increase the risk of recurrence and treatment intensification. Additionally, Ekbom et al. and Lutgens MW et al. also reported a close relationship between colorectal cancer and disease expansion. Therefore, quantifying the inflammatory load is crucial for individualized treatment of UC patients. However, the MES and UCEIS scoring systems only consider the most severely affected intestinal segment, thereby underestimating the actual disease range and burden. For example, for a patient with total colitis, multiple large ulcers, and a baseline Mayo endoscopic score of 3, if there is improvement after treatment but still has a single ulcer in the sigmoid colon, the Mayo endoscopic score remains 3 and belongs to endoscopic non-response.
The Ulcerative Colitis Colon Severity Index (UCCIS) takes into account four different variables (granularity, vascular pattern, ulcers, and bleeding-fragility) for all colon segments and shows correlation with clinical indicators and laboratory parameters of disease activity. However, due to the small sample size, its feasibility and simplicity need to be proven in clinical practice. The Modified Mayo Endoscopic Score (MMES) is based on the Mayo endoscopic score and combines the degree of mucosal inflammation and lesion distribution in different intestinal segments, better reflecting endoscopic response and improvement numerically. However, this score does not have a clear boundary for disease severity and lacks inter-rater and inter-observer consistency validation, which may change the proportion of patients defined as remission and affect treatment or regulatory decisions. The DUBLIN scoring method for the degree of luminal inflammation burden in ulcerative colitis, published by Rowan et al. in 2019, is the product of MES (0-3) and the disease lesion range (E1-E3). This scoring method shows a good correlation with MES, UCEIS, fecal calcium protein, and other inflammatory markers, as well as histological activity. However, due to the single-center study and the small sample size, the inter-observer and intra-observer consistency has not yet been verified.
At present, there are few data on how endoscopic changes in the short and medium term affect long-term clinical outcomes. By combining the advantages and limitations of different UC endoscopic scoring systems published previously, we propose a new endoscopic scoring system - the CAT-DESIRE score. We hope to evaluate the reliability and validity of the CAT-DESIRE score, verify its predictive role in medium- and long-term prognosis, therapeutic efficacy and adjustment, and provide a reliable and simple tool for comprehensive and accurate assessment of the disease burden and treatment effect of UC patients, in order to better guide clinical treatment decisions.
- Conditions
- Ulcerative Colitis (UC)
- Medical subject headings
- Colitis, Ulcerative
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| CAT-DESIRE Assessment Group | 1. Multiple centers recruit participants, and the collection of the following participant information, two clear colonoscopy images, age, gender, BMI, lesion range, duration of the disease, extraintestinal manifestations, history of related surgeries for ulcerative colitis, routine blood tests, serum albumin, erythrocyte sedimentation rate, C-reactive protein, drug treatment and adjustment status; 2. Conducting Mayo endoscopy scoring, UCEIS scoring, MMES scoring, and CAT-DESIRE scoring for the two colonoscopy images of the participants; |
What is being measured
The primary outcome is the main question the study is designed to answer.
The two clear colonoscopy images before and after the treatment
Two clear colonoscopy images before and after treatment must include at least one photo of each of the seven parts: the terminal ileum, cecum, ascending colon, transverse colon, descending colon, sigmoid colon, and rectum. A single researcher reviews the quality of the colonoscopy images and selects records with satisfactory quality (clear images and adequate bowel preparation).
Measured: Three months after receiving any standard UC treatment , including mesalazine, steroids, immunosuppressants, biologics and small molecule drugs, etc.
Secondary outcomes (6)
Blood white blood cell count test
Blood white blood cell count test results
Measured: Three months after receiving any standard UC treatment, including mesalazine, steroids, immunosuppressants, biologics and small molecule drugs.
Hemoglobin
Hemoglobin test results
Measured: Three months after receiving any standard UC treatment, including mesalazine, steroids, immunosuppressants, biologics and small molecule drugs.
Platelet count test
Platelet count test results
Measured: Three months after receiving any standard UC treatment, including mesalazine, steroids, immunosuppressants, biologics and small molecule drugs.
Serum albumin test
Serum albumin test results
Measured: Three months after receiving any standard UC treatment, including mesalazine, steroids, immunosuppressants, biologics and small molecule drugs.
ESR
Erythrocyte sedimentation rates
Measured: Three months after receiving any standard UC treatment, including mesalazine, steroids, immunosuppressants, biologics and small molecule drugs.
CRP
C-reactive protein test results
Measured: Three months after receiving any standard UC treatment, including mesalazine, steroids, immunosuppressants, biologics and small molecule drugs.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 May 2026
- Study start1 Feb 2024
- Primary completion1 Dec 2025
- Study completion1 May 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (10)Papers the sponsor has linked to this study.
- Other trials for Ulcerative Colitis (UC)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 235 participants (actual)
Sponsor and investigators
- Lead sponsor
- Xijing Hospital of Digestive Diseases
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Jie Liang, Xijing Hospital of Digestive Diseases
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07608198
- Sponsor's protocol ID
- XijingHDD-UC-CAT-DESIRE
- Other IDs
- 82370588, 82570614, XJZT25CX41
- Status last verified
- May 2026
- First submitted
- 12 May 2026
- Last updated
- 27 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005 Dec 8;353(23):2462-76. doi: 10.1056/NEJMoa050516.
PubMed 16339095Travis SP, Schnell D, Krzeski P, Abreu MT, Altman DG, Colombel JF, Feagan BG, Hanauer SB, Lemann M, Lichtenstein GR, Marteau PR, Reinisch W, Sands BE, Yacyshyn BR, Bernhardt CA, Mary JY, Sandborn WJ. Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut. 2012 Apr;61(4):535-42. doi: 10.1136/gutjnl-2011-300486. Epub 2011 Oct 13.
PubMed 21997563BARON JH, CONNELL AM, LENNARD-JONES JE. VARIATION BETWEEN OBSERVERS IN DESCRIBING MUCOSAL APPEARANCES IN PROCTOCOLITIS. Br Med J. 1964 Jan 11;1(5375):89-92. doi: 10.1136/bmj.1.5375.89. No abstract available.
PubMed 14075156Harbord M, Eliakim R, Bettenworth D, Karmiris K, Katsanos K, Kopylov U, Kucharzik T, Molnar T, Raine T, Sebastian S, de Sousa HT, Dignass A, Carbonnel F; European Crohn's and Colitis Organisation [ECCO]. Corrigendum: Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management. J Crohns Colitis. 2017 Dec 4;11(12):1512. doi: 10.1093/ecco-jcc/jjx105. No abstract available.
PubMed 29088340Lichtenstein GR, Rutgeerts P. Importance of mucosal healing in ulcerative colitis. Inflamm Bowel Dis. 2010 Feb;16(2):338-46. doi: 10.1002/ibd.20997.
PubMed 19637362Colombel JF, Rutgeerts P, Reinisch W, Esser D, Wang Y, Lang Y, Marano CW, Strauss R, Oddens BJ, Feagan BG, Hanauer SB, Lichtenstein GR, Present D, Sands BE, Sandborn WJ. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology. 2011 Oct;141(4):1194-201. doi: 10.1053/j.gastro.2011.06.054. Epub 2011 Jun 30.
PubMed 21723220Ardizzone S, Cassinotti A, Duca P, Mazzali C, Penati C, Manes G, Marmo R, Massari A, Molteni P, Maconi G, Porro GB. Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. Clin Gastroenterol Hepatol. 2011 Jun;9(6):483-489.e3. doi: 10.1016/j.cgh.2010.12.028. Epub 2010 Dec 31.
PubMed 21195796Le Berre C, Ricciuto A, Peyrin-Biroulet L, Turner D. Evolving Short- and Long-Term Goals of Management of Inflammatory Bowel Diseases: Getting It Right, Making It Last. Gastroenterology. 2022 Apr;162(5):1424-1438. doi: 10.1053/j.gastro.2021.09.076. Epub 2022 Jan 4.
PubMed 34995529D'Haens G, Sandborn WJ, Feagan BG, Geboes K, Hanauer SB, Irvine EJ, Lemann M, Marteau P, Rutgeerts P, Scholmerich J, Sutherland LR. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007 Feb;132(2):763-86. doi: 10.1053/j.gastro.2006.12.038. Epub 2006 Dec 20. No abstract available.
PubMed 17258735Raine T, Bonovas S, Burisch J, Kucharzik T, Adamina M, Annese V, Bachmann O, Bettenworth D, Chaparro M, Czuber-Dochan W, Eder P, Ellul P, Fidalgo C, Fiorino G, Gionchetti P, Gisbert JP, Gordon H, Hedin C, Holubar S, Iacucci M, Karmiris K, Katsanos K, Kopylov U, Lakatos PL, Lytras T, Lyutakov I, Noor N, Pellino G, Piovani D, Savarino E, Selvaggi F, Verstockt B, Spinelli A, Panis Y, Doherty G. ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment. J Crohns Colitis. 2022 Jan 28;16(1):2-17. doi: 10.1093/ecco-jcc/jjab178. No abstract available.
PubMed 34635919
Study at a glance
From the registry record, last updated by the sponsor on 27 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Validation of the Reliability and Validity of the New Endoscopic Scoring System for Ulcerative Colitis (CAT-DESIRE Score) and Verification of Its Clinical Practicability
- ClinicalTrials.gov ID
- NCT07608198
- Acronym / sponsor ID
- XijingHDD-UC-CAT-DESIRE
- Conditions
- Ulcerative Colitis (UC)
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 235 participants (actual)
- Lead sponsor
- Xijing Hospital of Digestive DiseasesUniversity, hospital or other
- Study start
- 1 Feb 2024 (actual)
- Primary completion
- 1 Dec 2025 (actual)
- Study completion
- 1 May 2026 (actual)
- First posted
- 27 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Ulcerative Colitis (UC) is a chronic, non-specific intestinal inflammatory disease of unknown cause, featuring abdominal pain, diarrhea, and bloody stools. Endoscopy shows diffuse, continuous lesions with erosion and shallow ulcers, worst in the rectum and diminishing proximally. Current treatments (aminosalicylates, corticosteroids, immunosuppressants, biologics, small molecule drugs) are not curative. Endoscopic mucosal healing is a key treatment goal, improving steroid-free remission, reducing colectomy rates, recurrence, hospitalization, and colorectal cancer risk.
Common endoscopic scoring systems: Baron score (poor consistency), Mayo Endoscopic Score (MES, simple but lacks prognostic info), and Ulcerative Colitis Endoscopic Severity Index (UCEIS, more detailed and consistent but cumbersome). Disease extent is important for severity, as proximal extension increases relapse, treatment escalation, and cancer risk. However, MES and UCEIS assess only the worst segment, underestimating total disease burden.
Other scores (UCCIS, MMES, DUBLIN) attempt to incorporate lesion extent but have limitations (small samples, lack of validation, unclear severity cutoffs). Data on short-/medium-term endoscopic changes and long-term outcomes are scarce.
We therefore propose a new endoscopic scoring system, the CAT-DESIRE score, aiming to evaluate its reliability, validity, and predictive role in medium-/long-term prognosis and treatment response, providing a simple, accurate tool for assessing disease burden and guiding clinical decisions.
Detailed description
Ulcerative Colitis (UC) is a chronic, non-specific inflammatory disease of the intestine with unknown causes and mechanisms. Its main clinical manifestations include abdominal pain, diarrhea, and bloody stools. The typical endoscopic appearance of UC is diffuse and continuous lesions, accompanied by erosion and shallow ulcers. The lesions are most severe in the rectum and gradually become less severe towards the proximal part. Currently, the main therapeutic drugs for UC include aminosalicylic acid preparations, corticosteroids, immunosuppressants, biologics, and small molecule drugs, but there is no cure. The choice of treatment plan is based on a comprehensive assessment of the disease. Endoscopic examination can objectively determine the lesion range and assess the disease activity, which is of great significance for monitoring treatment response and providing individualized optimal treatment plans. Endoscopic mucosal healing has become an important goal in the treatment of UC, and it has been proven to achieve better long-term efficacy, including increasing the rate of steroid-free remission, reducing the need for colectomy, and lowering the risks of recurrence, hospitalization, and colorectal cancer.
There are several endoscopic scoring systems currently applied in clinical and research assessment of UC. Different endoscopic scoring tools have different advantages and limitations. The initial endoscopic classification of UC was the Baron score, which, due to not measuring the consistency indicators among researchers, had a 40% disagreement in classifying normal, mild, moderate, or severe activity, and there was little supporting data. The Mayo endoscopic score (MES) and the Ulcerative Colitis Endoscopic Severity Index (UCEIS) are currently the two main endoscopic scoring systems for evaluating mucosal inflammation symptoms and disease activity. MES is easy to use but lacks information on disease prognosis. UCEIS distinguishes mucosal inflammation and disease activity more detailedly through a greater number of layers (0-8) than MES (0-3), and shows higher internal and inter-rater consistency, but is more computationally cumbersome.
The disease range is potentially important in evaluating the severity of UC. The IBSEN study showed that disease expansion is an important independent factor for colectomy in UC patients. Qiu and his colleagues further proved that proximal disease expansion would increase the risk of recurrence and treatment intensification. Additionally, Ekbom et al. and Lutgens MW et al. also reported a close relationship between colorectal cancer and disease expansion. Therefore, quantifying the inflammatory load is crucial for individualized treatment of UC patients. However, the MES and UCEIS scoring systems only consider the most severely affected intestinal segment, thereby underestimating the actual disease range and burden. For example, for a patient with total colitis, multiple large ulcers, and a baseline Mayo endoscopic score of 3, if there is improvement after treatment but still has a single ulcer in the sigmoid colon, the Mayo endoscopic score remains 3 and belongs to endoscopic non-response.
The Ulcerative Colitis Colon Severity Index (UCCIS) takes into account four different variables (granularity, vascular pattern, ulcers, and bleeding-fragility) for all colon segments and shows correlation with clinical indicators and laboratory parameters of disease activity. However, due to the small sample size, its feasibility and simplicity need to be proven in clinical practice. The Modified Mayo Endoscopic Score (MMES) is based on the Mayo endoscopic score and combines the degree of mucosal inflammation and lesion distribution in different intestinal segments, better reflecting endoscopic response and improvement numerically. However, this score does not have a clear boundary for disease severity and lacks inter-rater and inter-observer consistency validation, which may change the proportion of patients defined as remission and affect treatment or regulatory decisions. The DUBLIN scoring method for the degree of luminal inflammation burden in ulcerative colitis, published by Rowan et al. in 2019, is the product of MES (0-3) and the disease lesion range (E1-E3). This scoring method shows a good correlation with MES, UCEIS, fecal calcium protein, and other inflammatory markers, as well as histological activity. However, due to the single-center study and the small sample size, the inter-observer and intra-observer consistency has not yet been verified.
At present, there are few data on how endoscopic changes in the short and medium term affect long-term clinical outcomes. By combining the advantages and limitations of different UC endoscopic scoring systems published previously, we propose a new endoscopic scoring system - the CAT-DESIRE score. We hope to evaluate the reliability and validity of the CAT-DESIRE score, verify its predictive role in medium- and long-term prognosis, therapeutic efficacy and adjustment, and provide a reliable and simple tool for comprehensive and accurate assessment of the disease burden and treatment effect of UC patients, in order to better guide clinical treatment decisions.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| CAT-DESIRE Assessment Group | – | –1. Multiple centers recruit participants, and the collection of the following participant information, two clear colonoscopy images, age, gender, BMI, lesion range, duration of the disease, extraintestinal manifestations, history of related surgeries for ulcerative colitis, routine blood tests, serum albumin, erythrocyte sedimentation rate, C-reactive protein, drug treatment and adjustment status; 2. Conducting Mayo endoscopy scoring, UCEIS scoring, MMES scoring, and CAT-DESIRE scoring for the two colonoscopy images of the participants; |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- A total of 235 UC patients were recruited from 9 specialized IBD diagnosis and therapy centers across China, with all patients undergoing paired endoscopic evaluations. Nine specialized IBD diagnosis and therapy centers are the Air Force Military Medical University First Affiliated Hospital, the Beijing Peking Union Medical College Hospital, the Xi'an Jiaotong University Affiliated Second Hospital, the Shanghai Ruijin Hospital, the Xinjiang Urumqi Affiliated First Hospital, the Sichuan Huaxi Hospital, the Wuhan Xiehe Hospital, the Shanghai Jiao Tong Renji Hospital, and the Seventh Medical Center of PLA General Hospital.
Key inclusion criteria (4 listed)
- 1. Adult patients (aged 18 - 75 years);
- 2. Diagnosed with ulcerative colitis for at least 3 months;
- 3. Have had endoscopic examination results for at least 2 times, with clear endoscopic images (including endoscopic pictures of the terminal ileum, cecum, ascending colon, transverse colon, descending colon, sigmoid colon, and rectum at least one picture for each of these 7 areas);
- 4. Complete clinical data.
Key exclusion criteria (2 listed)
- 1. Crohn's disease, intestinal Behcet's disease, intestinal tuberculosis, toxic megacolon and unclassified inflammatory bowel disease.
- 2. The length of the colon lesion could not be evaluated.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
The two clear colonoscopy images before and after the treatment
Time frame: Three months after receiving any standard UC treatment , including mesalazine, steroids, immunosuppressants, biologics and small molecule drugs, etc.
Two clear colonoscopy images before and after treatment must include at least one photo of each of the seven parts: the terminal ileum, cecum, ascending colon, transverse colon, descending colon, sigmoid colon, and rectum. A single researcher reviews the quality of the colonoscopy images and selects records with satisfactory quality (clear images and adequate bowel preparation).
6 secondary outcomes
Blood white blood cell count test
Time frame: Three months after receiving any standard UC treatment, including mesalazine, steroids, immunosuppressants, biologics and small molecule drugs.
Hemoglobin
Time frame: Three months after receiving any standard UC treatment, including mesalazine, steroids, immunosuppressants, biologics and small molecule drugs.
Platelet count test
Time frame: Three months after receiving any standard UC treatment, including mesalazine, steroids, immunosuppressants, biologics and small molecule drugs.
Serum albumin test
Time frame: Three months after receiving any standard UC treatment, including mesalazine, steroids, immunosuppressants, biologics and small molecule drugs.
ESR
Time frame: Three months after receiving any standard UC treatment, including mesalazine, steroids, immunosuppressants, biologics and small molecule drugs.
CRP
Time frame: Three months after receiving any standard UC treatment, including mesalazine, steroids, immunosuppressants, biologics and small molecule drugs.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 May 2026.
- Background: PubMed 16339095Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005 Dec 8;353(23):2462-76. doi: 10.1056/NEJMoa050516.
- Background: PubMed 21997563Travis SP, Schnell D, Krzeski P, Abreu MT, Altman DG, Colombel JF, Feagan BG, Hanauer SB, Lemann M, Lichtenstein GR, Marteau PR, Reinisch W, Sands BE, Yacyshyn BR, Bernhardt CA, Mary JY, Sandborn WJ. Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut. 2012 Apr;61(4):535-42. doi: 10.1136/gutjnl-2011-300486. Epub 2011 Oct 13.
- Background: PubMed 14075156BARON JH, CONNELL AM, LENNARD-JONES JE. VARIATION BETWEEN OBSERVERS IN DESCRIBING MUCOSAL APPEARANCES IN PROCTOCOLITIS. Br Med J. 1964 Jan 11;1(5375):89-92. doi: 10.1136/bmj.1.5375.89. No abstract available.
- Background: PubMed 29088340Harbord M, Eliakim R, Bettenworth D, Karmiris K, Katsanos K, Kopylov U, Kucharzik T, Molnar T, Raine T, Sebastian S, de Sousa HT, Dignass A, Carbonnel F; European Crohn's and Colitis Organisation [ECCO]. Corrigendum: Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management. J Crohns Colitis. 2017 Dec 4;11(12):1512. doi: 10.1093/ecco-jcc/jjx105. No abstract available.
- Background: PubMed 19637362Lichtenstein GR, Rutgeerts P. Importance of mucosal healing in ulcerative colitis. Inflamm Bowel Dis. 2010 Feb;16(2):338-46. doi: 10.1002/ibd.20997.
- Background: PubMed 21723220Colombel JF, Rutgeerts P, Reinisch W, Esser D, Wang Y, Lang Y, Marano CW, Strauss R, Oddens BJ, Feagan BG, Hanauer SB, Lichtenstein GR, Present D, Sands BE, Sandborn WJ. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology. 2011 Oct;141(4):1194-201. doi: 10.1053/j.gastro.2011.06.054. Epub 2011 Jun 30.
- Background: PubMed 21195796Ardizzone S, Cassinotti A, Duca P, Mazzali C, Penati C, Manes G, Marmo R, Massari A, Molteni P, Maconi G, Porro GB. Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. Clin Gastroenterol Hepatol. 2011 Jun;9(6):483-489.e3. doi: 10.1016/j.cgh.2010.12.028. Epub 2010 Dec 31.
- Background: PubMed 34995529Le Berre C, Ricciuto A, Peyrin-Biroulet L, Turner D. Evolving Short- and Long-Term Goals of Management of Inflammatory Bowel Diseases: Getting It Right, Making It Last. Gastroenterology. 2022 Apr;162(5):1424-1438. doi: 10.1053/j.gastro.2021.09.076. Epub 2022 Jan 4.
- Background: PubMed 17258735D'Haens G, Sandborn WJ, Feagan BG, Geboes K, Hanauer SB, Irvine EJ, Lemann M, Marteau P, Rutgeerts P, Scholmerich J, Sutherland LR. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007 Feb;132(2):763-86. doi: 10.1053/j.gastro.2006.12.038. Epub 2006 Dec 20. No abstract available.
- Background: PubMed 34635919Raine T, Bonovas S, Burisch J, Kucharzik T, Adamina M, Annese V, Bachmann O, Bettenworth D, Chaparro M, Czuber-Dochan W, Eder P, Ellul P, Fidalgo C, Fiorino G, Gionchetti P, Gisbert JP, Gordon H, Hedin C, Holubar S, Iacucci M, Karmiris K, Katsanos K, Kopylov U, Lakatos PL, Lytras T, Lyutakov I, Noor N, Pellino G, Piovani D, Savarino E, Selvaggi F, Verstockt B, Spinelli A, Panis Y, Doherty G. ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment. J Crohns Colitis. 2022 Jan 28;16(1):2-17. doi: 10.1093/ecco-jcc/jjab178. No abstract available.
- Individual participant dataSharing planned: No
Related trials for Ulcerative Colitis (UC)
RecruitingObservational study
Ibd CAncer and seRious Infections in France (I-CARE 2)
IBD, Ulcerative Colitis
Not yet recruitingObservational study
Non-Invasive Biomarker Monitoring in UC on Biologics
Ulcerative Colitis
RecruitingPhase 2
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate
RecruitingPhase 1/2
Safety, Dosage, and Microbiome Engraftment Study of MGT-006 for Ulcerative Colitis (ROOT Study)
Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate
RecruitingPhase 1/2
Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis
Ulcerative Colitis (UC)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
9 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Ulcerative Colitis (UC), run by Xijing Hospital of Digestive Diseases at 9 sites in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 27 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 9 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The two clear colonoscopy images before and after the treatment (time frame: Three months after receiving any standard UC treatment , including mesalazine, steroids, immunosuppressants, biologics and small molecule drugs, etc.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07608198, which also lists 10 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 May 2026.